导航
| 统计阶段 | 收益率 | 同类排名 |
|---|---|---|
| 今年以来 | 15.96% | 416/4773 |
| 近一周 | -2.46% | 2241/5462 |
| 近一月 | -9.59% | 4773/5421 |
| 近一季 | -11.02% | 3635/5209 |
| 近半年 | 13.38% | 359/4920 |
| 近一年 | 16.74% | 575/4366 |
| 近两年 | 139.21% | 264/2954 |
| 近三年 | 76.76% | 237/2253 |
| 成立以来 | -0.80% | - |
| 年份 | 年收益 | 1季度 | 2季度 | 3季度 | 4季度 |
| 2026 | - - |
-6.38% 4117/4961 |
75.88% 203/5312 |
- - |
- - |
| 2025 | 36.63% 936/4813 |
3.26% 1139/3635 |
-1.67% 3244/4076 |
49.26% 344/4524 |
-9.84% 4098/4813 |
| 2024 | 16.09% 849/3463 |
-10.59% 2354/2808 |
-6.50% 1967/3014 |
22.39% 476/3129 |
13.45% 144/3463 |
| 2023 | -11.26% 1386/2656 |
12.28% 305/2280 |
-6.86% 1729/2385 |
-11.62% 2079/2515 |
-3.98% 837/2655 |
| 2022 | -31.61% 1661/2207 |
-21.91% 1665/1919 |
1.50% 1466/2016 |
-15.18% 1235/2113 |
1.72% 1169/2208 |
| 2021 | 1.08% 692/1822 |
-10.47% 1114/1255 |
27.66% 58/1330 |
-13.57% 1349/1466 |
2.31% 627/1822 |
| 2020 | - - |
- - |
- - |
- - |
-0.58% 1080/1184 |
| 2019 | - - |
- - |
- - |
- - |
- - |
| 2018 | - - |
- - |
- - |
- - |
- - |
| 2017 | - - |
- - |
- - |
- - |
- - |
| 2016 | - - |
- - |
- - |
- - |
- - |
| 2015 | - - |
- - |
- - |
- - |
- - |
| 2014 | - - |
- - |
- - |
- - |
- - |
| 2013 | - - |
- - |
- - |
- - |
- - |
| 基金名称 | 最新净值 | 季增长率 |
| 万家中证港股通创新药ETF | 1.5896 | 28.31% |
| 景顺长城中证港股通创新药ETF | 1.6507 | 28.23% |
| 港股医疗 | 0.9366 | 28.18% |
| 港股医疗ETF | 1.4282 | 28.15% |
| 港股通医疗ETF工银 | 0.9464 | 28.06% |
| 港股通医疗ETF华宝 | 0.9577 | 27.97% |
| 天弘恒生沪深港创新药精选50ETF发起联接C | 1.2844 | 27.92% |
| 天弘恒生沪深港创新药精选50ETF | 0.8437 | 27.35% |
| 万家中证港股通创新药ETF发起式联接A | 1.3863 | 27.32% |
| 万家中证港股通创新药ETF发起式联接C | 1.3856 | 27.27% |
| 易方达上证科创板50成份ETF VS. 长安沪深300非周期A(740101) |